BE634903A - - Google Patents
Info
- Publication number
- BE634903A BE634903A BE634903DA BE634903A BE 634903 A BE634903 A BE 634903A BE 634903D A BE634903D A BE 634903DA BE 634903 A BE634903 A BE 634903A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- dogs
- virus
- contagious
- leptospira
- Prior art date
Links
- 241000282472 Canis lupus familiaris Species 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 39
- 229960005486 vaccines Drugs 0.000 claims description 29
- 208000006454 Hepatitis Diseases 0.000 claims description 28
- 231100000283 hepatitis Toxicity 0.000 claims description 28
- 208000000655 Distemper Diseases 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 17
- 241000589902 Leptospira Species 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 206010024238 Leptospirosis Diseases 0.000 claims description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 210000001519 tissues Anatomy 0.000 claims description 9
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 244000052616 bacterial pathogens Species 0.000 claims description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 241000282421 Canidae Species 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 210000000952 Spleen Anatomy 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 241001310793 Podium Species 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 261
- 238000002255 vaccination Methods 0.000 description 13
- 201000009910 diseases by infectious agent Diseases 0.000 description 11
- 230000003472 neutralizing Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 102000004965 antibodies Human genes 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 230000001717 pathogenic Effects 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010047903 Weil's disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 101710026914 AAG Proteins 0.000 description 1
- 210000003165 Abomasum Anatomy 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 208000005252 Hepatitis A Diseases 0.000 description 1
- 206010019780 Hepatitis infectious Diseases 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000005158 Phaseolus vulgaris Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 239000010807 litter Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000405 serological Effects 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE634903A true BE634903A (de) |
Family
ID=201705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE634903D BE634903A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE634903A (de) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2010678A1 (en) * | 1968-06-11 | 1970-02-20 | Merieux Inst | Stable polyvalent vaccine for treatment of dogs - active against Carre's disease, hepatitis and leptospirosis |
| FR2016289A1 (en) * | 1968-08-23 | 1970-05-08 | Behringwerke Ag | Carre's disease combined vaccine - from measles type virus |
-
0
- BE BE634903D patent/BE634903A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2010678A1 (en) * | 1968-06-11 | 1970-02-20 | Merieux Inst | Stable polyvalent vaccine for treatment of dogs - active against Carre's disease, hepatitis and leptospirosis |
| FR2016289A1 (en) * | 1968-08-23 | 1970-05-08 | Behringwerke Ag | Carre's disease combined vaccine - from measles type virus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO144005B (no) | Skistoevel. | |
| Fohlman et al. | Vaccination of Balb/c mice against enteroviral mediated myocarditis | |
| BE634903A (de) | ||
| CN112280750B (zh) | 具有跨种传播能力的新型鹅星状病毒及其应用 | |
| Kingdon et al. | Biochemical and immunological effects of Listeria monocytogenes hemolysin | |
| Sbenberg et al. | A new leptospiral vaccine for use in man. I. Development of a vaccine from Leptospira grown on a chemically defined medium | |
| CN104888213A (zh) | 一种猪瘟脾淋源复合活疫苗的制备方法 | |
| CN108588034B (zh) | 一种变异的兔病毒性出血症病毒及其在制备灭活疫苗中的应用 | |
| OSMAN et al. | Studies on causes of abortion in Maghrabian camels | |
| CN114350618A (zh) | 一种猪流行性腹泻病毒及其应用 | |
| CN113736752A (zh) | 兔病毒性出血症病毒2型及其在制备灭活疫苗中的应用 | |
| Van den Ende et al. | Experiments with the soluble antigen of rabies in suckling mouse brains | |
| Tamam | Isolation of Lumpy skin disease virus form naturally infected cattle previously vaccinated with live attenuated sheep poxvirus vaccine | |
| Abbas et al. | Production of goat pox virus vaccine from a live attenuated goat pox virus strain. | |
| Gordon | Investigating the role of persisting antigen in immunity against foot-and-mouth disease virus | |
| JPS58159423A (ja) | パスツレラムルトシダ菌株の培養による免疫抗原の製造方法 | |
| Quersin-Thiry | Action of Anticellular Sera on Virus Infections: II. Influence on Heterologous Tissue Cultures | |
| Shahzad | COMPARATIVE EVALUATION OF ANTIBODY TITER AGAINST PASTEURELLA MULTOCIDA IN RABBITS BY USING FOUR DIFFERENT ADJUVANTS IN HS+ BQ COMBO VACCINES | |
| Zhugunissov et al. | DETERMINATION OF IMMUNIZING DOSES OF THE COWPOX VACCINE CANDIDATE: PRELIMINARY RESULTS | |
| WO2000029018A1 (fr) | Vaccin combine contre l'hepatite a et la rougeole et son procede de preparation | |
| Stevenson et al. | Rinderpest vaccination and the incidence and development of trypanosomosis in cattle | |
| BE554749A (de) | ||
| Morgan | Section E. Diseases of dairy cattle. Brucellosis | |
| Magnusson | Possible Spread of Foot-and-Mouth Disease Through Cow-Pox Vaccine.—Recent Experiences in Norway | |
| RU2389791C1 (ru) | Штамм "вниизж 2003" вируса оспы коз variola virus caprinum для изготовления биопрепаратов для диагностики и специфической профилактики оспы коз |